Cecile P. G. Meier-Scherling
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cecile P. G. Meier-Scherling has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Jeffrey A. Bailey
Brown University, Providence, USA
5 shared publications - Oliver John Watson
Imperial College London
4 shared publications - George A. Tollefson
Brown University, Providence, RI, USA
3 shared publications - Isabela Gerdes Gyuricza
University of North Carolina, Chapel Hill, NC, USA
3 shared publications - Jonathan J. Juliano
University of North Carolina at Chapel Hill, Chapel Hill, USA
3 shared publications - Melissa D. Conrad
Johns Hopkins Malaria Research Institute, Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, USA
3 shared publications
Latest Publications
- Open Access
- 3 January 2026
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 42 (2)
Characterizing clinical toxicity in cancer combination therapies
Motivation: Predicting synergistic cancer drug combinations through computational methods offers a scalable approach to creating therapies that are more effective and less toxic. However, most algorithms focus solely on synergy without considering toxicity when selecting optimal drug combinations. In the absence of combinatorial toxicity assays, a few models use toxicity penalties to balance high synergy with lower toxicity. Still, these penalties have not been explicitly validated against known drug-drug interactions. Results: In this study, we examine whether synergy scores and toxicity metrics correlate with known adverse drug interactions. While some metrics show trends with toxicity levels, our results reveal significant limitations in using them as penalties. These findings highlight the challenges of incorporating toxicity into synergy prediction frameworks and suggest that advancing the field requires more comprehensive combination toxicity data. Availability and implementation: The code written for this project is available at https://github.com/amw14/toxicity-cancer-drug-combination.
- 3 January 2026
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 42 (2)
Open AccessCharacterizing clinical toxicity in cancer combination therapies
Motivation: Predicting synergistic cancer drug combinations through computational methods offers a scalable approach to creating therapies that are more effective and less toxic. However, most algorithms focus solely on synergy without considering toxicity when selecting optimal drug combinations. In the absence of combinatorial toxicity assays, a few models use toxicity penalties to balance high synergy with lower toxicity. Still, these penalties have not been explicitly validated against known drug-drug interactions. Results: In this study, we examine whether synergy scores and toxicity metrics correlate with known adverse drug interactions. While some metrics show trends with toxicity levels, our results reveal significant limitations in using them as penalties. These findings highlight the challenges of incorporating toxicity into synergy prediction frameworks and suggest that advancing the field requires more comprehensive combination toxicity data. Availability and implementation: The code written for this project is available at https://github.com/amw14/toxicity-cancer-drug-combination.
- Open Access
Mapping the prevalence of molecular markers of Plasmodium falciparum artemisinin partial resistance in Africa: a spatial-temporal modelling study
A bstract: Background: Plasmodium falciparum kelch13 ( k13 ) mutations in Africa signal emerging artemisinin partial resistance (ART-R), endangering malaria control by undermining artemisinin-based combination therapies (ACTs). Sparse surveillance obscures whether rising k13 ART-R prevalence reflects local emergence or geographic expansion. We aimed to model and infer high-resolution spatial-temporal prevalence of k13 ART-R and ACT partner-drug markers to inform public health policy. Methods: We conducted a systematic literature review (PROSPERO-ID CRD42024593923) spanning the years 2014–2025, complementing existing data from WWARN, MalariaGEN Pf7, and the WHO Malaria Threats Map. This integrated dataset, comprising 3,806 distinct molecular epidemiology surveys and 182,071 genotyped samples, was harmonized using a standardized data schema. We applied a spatial-temporal Gaussian process model to estimate the continuous prevalence of WHO k13 ART-R mutations, mdr1 86Y, and crt 76T. Findings: ART-R increases were driven by distinct emergences of k13 561H in Rwanda, k13 675V in Uganda, and k13 622I in Ethiopia and Eritrea. From 2012 to 2024, predicted k13 prevalence rose steadily in Northern Province, Uganda (1.81% per year) and Northern Province, Rwanda (3.49% per year), reaching 26.36% in Uganda and 39.44% in Rwanda by 2024. Modelling indicated a rapid transition from localized k13 ART-R mutation emergence to entrenched regional hotspots centred on Uganda–Rwanda and the Ethiopia–Eritrea border. Partner drug amodiaquine marker mdr1 86Y is fading, but crt 76T remains prevalent in the Horn of Africa. Interpretation: The rapid and multicentric expansion of k13 ART-R mutations in East Africa threatens ACT efficacy, especially where ART-R k13 and partner drug markers co-occur, mirroring early patterns observed before ACT failure in Southeast Asia. This study provides an updated k13 ART-R mutation database and high-resolution resistance maps with uncertainty quantification, demonstrating a crucial need to prioritize targeted molecular surveillance across greater East Africa to safeguard ACT efficacy. Funding: US National Institutes of Health. 1 Research in Context: Evidence before this study: We searched OVID MEDLINE and PubMed databases: Pubmed was searched from database inception to July 9th 2025, using the following search terms: (((((((plasmodium falciparum) OR (falciparum))) AND (Africa)) AND (((resistance) OR (kelch13) OR (pfkelch13) OR (k13) OR (crt) OR (pfcrt) OR (mdr1) OR (pfmdr1)))) AND (((Sequencing) OR (markers) OR (genotyping))). This search identified 922 publications, of which 116 meet our inclusion criteria. We extracted the prevalence of all WHO-validated and candidate k13 mutations (441L, 446I, 449A, 458Y, 469F, 469Y, 476I, 481V, 493H, 515K, 527H, 537I, 537D, 538V, 539T, 543T, 553L, 561H, 568G, 574L, 580Y, 622I, 675V), mdr1 86Y, and crt 76T for these studies. In Africa, ART-R resistance mutations have been increasingly detected beginning in 2013-2015, particularly in East Africa (Rwanda, Uganda) and the Horn of Africa (Ethiopia, Eritrea). Therapeutic efficacy studies (TES) generally show high ACT efficacy across the continent; nevertheless, the presence of k13 resistance mutations is viewed as a high-priority public health threat. Prior efforts to map these molecular markers have been hampered by sparse and heterogeneous sampling, resulting in prevalence maps that rely on simple aggregation with wide, uninformative uncertainty intervals, limiting utility for national programs seeking to identify true increases in resistance. Furthermore, sub-continental estimates have often been static or limited in their ability to model the spatial and temporal dynamics of distinct mutation lineages. Added value of this study: This study provides the largest and most current harmonized dataset of k13 ART-R and partner drug mutations in Africa with 182,071 samples and 3,806 surveys, integrating systematic literature review findings with major public databases (WWARN, MalariaGEN Pf7, and the WHO Malaria Threats Map). We used a spatial-temporal Gaussian process model to overcome the limitations of sparse sampling. This modelling approach enables the generation of continuous prevalence maps across space and time, simultaneously predicting prevalence in unsampled areas while rigorously quantifying the statistical uncertainty of those predictions. We provide the first contemporary, high-resolution maps that illustrate the concurrent selection dynamics of key partner drug markers ( mdr1 86Y and crt 76T) alongside the expanding focus of ART-R. Implications of all the available evidence: The dramatic rise in k13 ART-R mutations, coupled with the steady geographic expansion identified by our model, confirms that ART-R is now firmly established in East Africa. The colocalization of high prevalence k13 ART-R mutations in Uganda and Rwanda with near-fixation of markers related to partner drug tolerance creates a molecular resistance profile highly reminiscent of the conditions preceding widespread treatment failure in Southeast Asia. This suggests the need to more broadly shift away from reliance on artemether-lumefantrine and necessitates greater molecular surveillance in sub-Saharan Africa, prioritizing the identified high-prevalence regions (Uganda, Rwanda, Ethiopia, Eritrea) and neighboring countries. Our integrated approach provides the foundational, evidence-based tools needed by national malaria control programs (NMCPs) and the WHO to refine drug policy decisions before ART-R develops into clinical treatment failure.
Open AccessMapping the prevalence of molecular markers of Plasmodium falciparum artemisinin partial resistance in Africa: a spatial-temporal modelling study
A bstract: Background: Plasmodium falciparum kelch13 ( k13 ) mutations in Africa signal emerging artemisinin partial resistance (ART-R), endangering malaria control by undermining artemisinin-based combination therapies (ACTs). Sparse surveillance obscures whether rising k13 ART-R prevalence reflects local emergence or geographic expansion. We aimed to model and infer high-resolution spatial-temporal prevalence of k13 ART-R and ACT partner-drug markers to inform public health policy. Methods: We conducted a systematic literature review (PROSPERO-ID CRD42024593923) spanning the years 2014–2025, complementing existing data from WWARN, MalariaGEN Pf7, and the WHO Malaria Threats Map. This integrated dataset, comprising 3,806 distinct molecular epidemiology surveys and 182,071 genotyped samples, was harmonized using a standardized data schema. We applied a spatial-temporal Gaussian process model to estimate the continuous prevalence of WHO k13 ART-R mutations, mdr1 86Y, and crt 76T. Findings: ART-R increases were driven by distinct emergences of k13 561H in Rwanda, k13 675V in Uganda, and k13 622I in Ethiopia and Eritrea. From 2012 to 2024, predicted k13 prevalence rose steadily in Northern Province, Uganda (1.81% per year) and Northern Province, Rwanda (3.49% per year), reaching 26.36% in Uganda and 39.44% in Rwanda by 2024. Modelling indicated a rapid transition from localized k13 ART-R mutation emergence to entrenched regional hotspots centred on Uganda–Rwanda and the Ethiopia–Eritrea border. Partner drug amodiaquine marker mdr1 86Y is fading, but crt 76T remains prevalent in the Horn of Africa. Interpretation: The rapid and multicentric expansion of k13 ART-R mutations in East Africa threatens ACT efficacy, especially where ART-R k13 and partner drug markers co-occur, mirroring early patterns observed before ACT failure in Southeast Asia. This study provides an updated k13 ART-R mutation database and high-resolution resistance maps with uncertainty quantification, demonstrating a crucial need to prioritize targeted molecular surveillance across greater East Africa to safeguard ACT efficacy. Funding: US National Institutes of Health. 1 Research in Context: Evidence before this study: We searched OVID MEDLINE and PubMed databases: Pubmed was searched from database inception to July 9th 2025, using the following search terms: (((((((plasmodium falciparum) OR (falciparum))) AND (Africa)) AND (((resistance) OR (kelch13) OR (pfkelch13) OR (k13) OR (crt) OR (pfcrt) OR (mdr1) OR (pfmdr1)))) AND (((Sequencing) OR (markers) OR (genotyping))). This search identified 922 publications, of which 116 meet our inclusion criteria. We extracted the prevalence of all WHO-validated and candidate k13 mutations (441L, 446I, 449A, 458Y, 469F, 469Y, 476I, 481V, 493H, 515K, 527H, 537I, 537D, 538V, 539T, 543T, 553L, 561H, 568G, 574L, 580Y, 622I, 675V), mdr1 86Y, and crt 76T for these studies. In Africa, ART-R resistance mutations have been increasingly detected beginning in 2013-2015, particularly in East Africa (Rwanda, Uganda) and the Horn of Africa (Ethiopia, Eritrea). Therapeutic efficacy studies (TES) generally show high ACT efficacy across the continent; nevertheless, the presence of k13 resistance mutations is viewed as a high-priority public health threat. Prior efforts to map these molecular markers have been hampered by sparse and heterogeneous sampling, resulting in prevalence maps that rely on simple aggregation with wide, uninformative uncertainty intervals, limiting utility for national programs seeking to identify true increases in resistance. Furthermore, sub-continental estimates have often been static or limited in their ability to model the spatial and temporal dynamics of distinct mutation lineages. Added value of this study: This study provides the largest and most current harmonized dataset of k13 ART-R and partner drug mutations in Africa with 182,071 samples and 3,806 surveys, integrating systematic literature review findings with major public databases (WWARN, MalariaGEN Pf7, and the WHO Malaria Threats Map). We used a spatial-temporal Gaussian process model to overcome the limitations of sparse sampling. This modelling approach enables the generation of continuous prevalence maps across space and time, simultaneously predicting prevalence in unsampled areas while rigorously quantifying the statistical uncertainty of those predictions. We provide the first contemporary, high-resolution maps that illustrate the concurrent selection dynamics of key partner drug markers ( mdr1 86Y and crt 76T) alongside the expanding focus of ART-R. Implications of all the available evidence: The dramatic rise in k13 ART-R mutations, coupled with the steady geographic expansion identified by our model, confirms that ART-R is now firmly established in East Africa. The colocalization of high prevalence k13 ART-R mutations in Uganda and Rwanda with near-fixation of markers related to partner drug tolerance creates a molecular resistance profile highly reminiscent of the conditions preceding widespread treatment failure in Southeast Asia. This suggests the need to more broadly shift away from reliance on artemether-lumefantrine and necessitates greater molecular surveillance in sub-Saharan Africa, prioritizing the identified high-prevalence regions (Uganda, Rwanda, Ethiopia, Eritrea) and neighboring countries. Our integrated approach provides the foundational, evidence-based tools needed by national malaria control programs (NMCPs) and the WHO to refine drug policy decisions before ART-R develops into clinical treatment failure.
- Open Access
- 3 December 2025
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 113 (6) , 1169-1177
Toward Setting Minimum and Optimal Data to Report for Malaria Molecular Surveillance with Targeted Sequencing: The “What” and “Why”
: The coronavirus disease 2019 pandemic showcased the power of genomic surveillance in tracking infectious diseases, driving rapid public health responses, and global collaboration. This same infrastructure is being leveraged for malaria molecular surveillance (MMS) in Africa to address challenges such as artemisinin partial resistance and deletions in the Plasmodium falciparum histidine-rich protein 2 and 3 genes. However, variability in reporting sequencing methods and data reporting currently limits the validation, comparability, and reuse of data. To maximize the impact of MMS, minimal and optimal data that are key for validation and maximizing transparency and findable, accessible, interoperable, and reusable principles are proposed for reporting. Rather than focusing on specific data formats, in the current study, the authors propose what should be reported and why. Progressing to reporting individual infection-level polymorphism or microhaplotype data is central to maximizing the impact of MMS. Reporting must adhere to local regulatory practices and ensure proper data oversight and management, preventing data colonialism and preserving opportunities for data generators. With malaria’s challenges transcending borders, reporting and adopting standardized practices are essential to advancing research and strengthening global public health efforts.
- 3 December 2025
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 113 (6) , 1169-1177
Open AccessToward Setting Minimum and Optimal Data to Report for Malaria Molecular Surveillance with Targeted Sequencing: The “What” and “Why”
: The coronavirus disease 2019 pandemic showcased the power of genomic surveillance in tracking infectious diseases, driving rapid public health responses, and global collaboration. This same infrastructure is being leveraged for malaria molecular surveillance (MMS) in Africa to address challenges such as artemisinin partial resistance and deletions in the Plasmodium falciparum histidine-rich protein 2 and 3 genes. However, variability in reporting sequencing methods and data reporting currently limits the validation, comparability, and reuse of data. To maximize the impact of MMS, minimal and optimal data that are key for validation and maximizing transparency and findable, accessible, interoperable, and reusable principles are proposed for reporting. Rather than focusing on specific data formats, in the current study, the authors propose what should be reported and why. Progressing to reporting individual infection-level polymorphism or microhaplotype data is central to maximizing the impact of MMS. Reporting must adhere to local regulatory practices and ensure proper data oversight and management, preventing data colonialism and preserving opportunities for data generators. With malaria’s challenges transcending borders, reporting and adopting standardized practices are essential to advancing research and strengthening global public health efforts.
- Open Access
- 21 July 2025
- Published by MDPI AG in Preprints.org
Towards Setting Minimum and Optimal Data to Report for Malaria Molecular Surveillance with Targeted Sequencing: The “What” and the “Why”
The COVID-19 pandemic showcased the power of genomic surveillance in tracking infectious diseases, driving rapid public health responses, and global collaboration. This same infrastructure is being leveraged for malaria molecular surveillance (MMS) in Africa to tackle challenges like artemisinin partial resistance and Plasmodium falciparum histidine-rich protein 2 and 3 gene deletions. However, variability in reporting sequencing methods and data reporting is currently limiting the validation, comparability, and reuse of data. To maximize the impact of MMS, we propose minimal and optimal data for reporting that are key for validation and maximize transparency and FAIR (Findable, Accessible, Interoperable, Reusable) principles. Rather than focusing on specific data formats, here, we propose what should be reported and why. Moving to reporting individual infection-level polymorphism or microhaplotype data is central to maximizing the impact of MMS. Reporting must adhere to local regulatory practices and ensure proper data oversight and management, preventing data colonialism and preserving opportunities for data generators. With malaria’s challenges transcending borders, reporting and adopting standardized practices are essential to advance research and strengthen global public health efforts.
- 21 July 2025
- Published by MDPI AG in Preprints.org
Open AccessTowards Setting Minimum and Optimal Data to Report for Malaria Molecular Surveillance with Targeted Sequencing: The “What” and the “Why”
The COVID-19 pandemic showcased the power of genomic surveillance in tracking infectious diseases, driving rapid public health responses, and global collaboration. This same infrastructure is being leveraged for malaria molecular surveillance (MMS) in Africa to tackle challenges like artemisinin partial resistance and Plasmodium falciparum histidine-rich protein 2 and 3 gene deletions. However, variability in reporting sequencing methods and data reporting is currently limiting the validation, comparability, and reuse of data. To maximize the impact of MMS, we propose minimal and optimal data for reporting that are key for validation and maximize transparency and FAIR (Findable, Accessible, Interoperable, Reusable) principles. Rather than focusing on specific data formats, here, we propose what should be reported and why. Moving to reporting individual infection-level polymorphism or microhaplotype data is central to maximizing the impact of MMS. Reporting must adhere to local regulatory practices and ensure proper data oversight and management, preventing data colonialism and preserving opportunities for data generators. With malaria’s challenges transcending borders, reporting and adopting standardized practices are essential to advance research and strengthen global public health efforts.
- Open Access
- 17 March 2025
- Published by Elsevier in The Lancet Microbe
- Vol. 6 (5) , 101027
Selection of Plasmodium falciparum kelch13 mutations in Uganda in comparison with southeast Asia: a modelling study
- 17 March 2025
- Published by Elsevier in The Lancet Microbe
- Vol. 6 (5) , 101027
Open AccessSelection of Plasmodium falciparum kelch13 mutations in Uganda in comparison with southeast Asia: a modelling study
- Open Access
Selection of artemisinin partial resistance Kelch13 mutations in Uganda in 2016-22 was at a rate comparable to that seen previously in South-East Asia
Background: Artemisinin partial resistance, mediated by mutations in the Plasmodium falciparum Kelch13 protein (K13), rapidly spread in South-East Asia (SEA), undermining antimalarial efficacies of artemisinin-based combination therapies (ACT). Validated K13 mutations have recently arisen in Africa, but rates of increase are not well characterized. Methods: We investigated K13 mutation prevalence at 16 sites in Uganda (2016-2022, 6586 samples), and five sites in SEA (2003-2018, 5465 samples) by calculating selection coefficients using Bayesian mixed-effect linear models. We then tested whether SEA K13 mutation prevalence could have been forecast accurately using up to the first five years of available data and forecast future K13 mutation prevalence in Uganda. Findings: The selection coefficient for the prevalence of relevant K13 mutations (441L, 469F/Y, 561H, 675V) was estimated at s=0·383 (95% CrI: 0·247 - 0·528) per year, a 38% relative prevalence increase. Selection coefficients across Uganda were s=0·968 (0·463 - 1·569) for 441L, s=0·153 (- 0·445 - 0·727) for 469F, s=0·222 (−0·011 - 0·398) for 469Y, and s=0·152 (−0·023 - 0·312) for 675V. In SEA, the selection coefficient was s=−0·005 (−0·852 - 0·814) for 539T, s=0·574 (−0·092 - 1·201) for 580Y, and s=0·308 (0·089 - 0·536) for all validated K13 mutations. Forecast prevalences for Uganda assuming constant selection neared fixation (>95% prevalence) within a decade (2028-2033) for combined K13 mutations. Interpretation: The selection of K13 mutations in Uganda was at a comparable rate to that observed in SEA, suggesting K13 mutations may continue to increase quickly in Uganda. Funding: NIH R01AI156267, R01AI075045, and R01AI089674.
Open AccessSelection of artemisinin partial resistance Kelch13 mutations in Uganda in 2016-22 was at a rate comparable to that seen previously in South-East Asia
Background: Artemisinin partial resistance, mediated by mutations in the Plasmodium falciparum Kelch13 protein (K13), rapidly spread in South-East Asia (SEA), undermining antimalarial efficacies of artemisinin-based combination therapies (ACT). Validated K13 mutations have recently arisen in Africa, but rates of increase are not well characterized. Methods: We investigated K13 mutation prevalence at 16 sites in Uganda (2016-2022, 6586 samples), and five sites in SEA (2003-2018, 5465 samples) by calculating selection coefficients using Bayesian mixed-effect linear models. We then tested whether SEA K13 mutation prevalence could have been forecast accurately using up to the first five years of available data and forecast future K13 mutation prevalence in Uganda. Findings: The selection coefficient for the prevalence of relevant K13 mutations (441L, 469F/Y, 561H, 675V) was estimated at s=0·383 (95% CrI: 0·247 - 0·528) per year, a 38% relative prevalence increase. Selection coefficients across Uganda were s=0·968 (0·463 - 1·569) for 441L, s=0·153 (- 0·445 - 0·727) for 469F, s=0·222 (−0·011 - 0·398) for 469Y, and s=0·152 (−0·023 - 0·312) for 675V. In SEA, the selection coefficient was s=−0·005 (−0·852 - 0·814) for 539T, s=0·574 (−0·092 - 1·201) for 580Y, and s=0·308 (0·089 - 0·536) for all validated K13 mutations. Forecast prevalences for Uganda assuming constant selection neared fixation (>95% prevalence) within a decade (2028-2033) for combined K13 mutations. Interpretation: The selection of K13 mutations in Uganda was at a comparable rate to that observed in SEA, suggesting K13 mutations may continue to increase quickly in Uganda. Funding: NIH R01AI156267, R01AI075045, and R01AI089674.